EVALUATION OF IN VITRO HEPATIC TOXICITY OF LEAVES OF PTEROSPERMUM ACERIFOLIUM (L.) WILLD.
Objective: The objective of the study was to determine the in vitro hepatic toxicity profile of methanolic extract of leaves of Pterospermum acerifolium (L.) Willd. (MEPA) using a mammalian hepatic cell line (HepG2).
Methods: To assess its in vitro hepatic toxicity, 3-(4,5-dimethylthiazol-2-yl)-2,5-2,5-diphenyltetrazolium bromide assay using MEPA at a concentration of 25 μg, 50 μg, 100 μg, 200 μg, and 300 μg was carried out. Sorafenib tosylate was used as the standard agent to assess cytotoxicity.
Results: The inhibitory concentration 50 (IC50) value for HepG2 cell lines was determined after 24 h. Thereafter the cytotoxicity study was again performed with the ½ IC50, IC50, and 2IC50 doses of MEPA. Experimentally, the IC50 was found to be 150.42 μg/ml for HepG2 using MEPA. A dose-dependent cytotoxicity and reduction in optical density were also observed with incremental MEPA administration.
Conclusion: The cytotoxic potential of MEPA was found to be much less than that of sorafenib tosylate. Thus, MEPA shows in vitro cytotoxicity in mammalian hepatic cells (HepG2) at a concentration as low as 100 μg.
2. Chatterjee P, Chakraborty B, Dwivedi A, Datta R. Pterospermum acerifolium (L.) Willd: A comprehensive review with significant pharmacological activities. Int J Pharm Life Sci 2012;3:1153-8.
3. Basu KR, Basu BD. Indian Medicinal Plants. 2nd ed. New Delhi: Bishen Singh Mahendra Pal Singh; 1987.
4. Van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: The MTT assay. Methods Mol Biol 2011;731:237-45.
5. Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma ell line HepG2 with regard to their biotransformation properties. Drug Metab Dispos 2003;31:1035-42.
6. Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, et al. Primary hepatocytes: Current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Meta Rev 2007;39:159-234.
7. Sinz M, Kim S. Stem cells, immortalized cells and primary cells in ADMET assays. Drug Discov Today Technol 2006;3:79-85.
8. Soldatow VY, Le Cluyse EL, Griffith LG, Rusynet I. In vitro models for liver toxicity testing. Toxicol Res 2013;2:23-39.
9. Rodrigues RM, De Kock J, Branson S, Vinken M, Meganathan K, Chaudhari U, et al. Human skin-derived stem cells as a novel cell source for in vitro hepatotoxicity screening of pharmaceuticals. Stem Cells Dev 2014;23:44-55.
10. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: Old and new paradigms. Gastroenterology 2004;127:S56-61.
11. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004;127:S72-8.
12. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003;22:5093-107.
13. Dey S, Roy S, Deb N, Sen KK, Besra SE, Anti-carcinogenic activity of Ruellia tuberosa L. (Acanthaceae) leaf extract on hepatoma cell line ande increased superoxide dismutase activity on macrophage cell lysate. Int J Pharm Pharm Sci 2013;5:854-61.
14. Carter CA, Chen C, Brink C, Vincent P, Maxuitenko YY, Gilbert KS, et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemoth Pharm 2007;59:183-95.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.